Comprehensive Report: Ketotifen

I. Introduction and Drug Identification

• A. Overview of Ketotifen Ketotifen is a pharmaceutical agent recognized for its utility in managing various allergic conditions. Its therapeutic action stems from a dual mechanism, functioning both as a histamine H1 receptor antagonist (antihistamine) and as a mast cell stabilizer.3 This combination of activities allows it to address different facets of the allergic response. The drug is available in multiple formulations tailored for specific applications. Ophthalmic preparations, including eye drops and, more recently, drug-eluting contact lenses, are primarily employed for the symptomatic relief of allergic conjunctivitis, targeting ocular itching and irritation.3 Oral formulations, such as tablets and syrups, are utilized systemically for the prophylaxis of mild atopic asthma, particularly in pediatric populations in certain regions, and for the management of other allergic-type disorders.3
• B. Chemical Properties Ketotifen belongs to the benzocycloheptathiophene class of compounds.4 Chemically, the base form is identified as 4-(1-Methyl-4-piperidinylidene)-4,9-dihydro-10H-benzo1cyclohepta[1,2-b]thiophen-10-one.2 However, it is frequently formulated and administered as its hydrogen fumarate salt.5 The IUPAC name for the base is 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one 4, while the fumarate salt is named (E)-but-2-enedioic acid;2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one.7 Variations in nomenclature exist across sources.4 The molecular formula for the ketotifen base is C19​H19​NOS [1], with a corresponding molecular weight of approximately 309.43 g/mol.[1] The fumarate salt has the molecular formula C23​H23​NO5​S and a molecular weight of 425.50 g/mol.[5] The distinction between the base and the salt form is critical, as the fumarate is the entity present in many marketed pharmaceutical products [5], and failing to specify the form can lead to inaccuracies in dosage calculations or interpretation of physicochemical data. The Chemical Abstracts Service (CAS) Registry Number for the ketotifen base is 34580-13-7 [4], and for the fumarate salt is 34580-14-8.[3] Physically, ketotifen fumarate is described as a finely crystalline powder [5], ranging in color from white to brownish-yellow.[18] It exhibits limited solubility, being sparingly soluble in water and slightly soluble in methanol.[18] Its LogP value suggests lipophilicity [3], a property consistent with its ability to cross the blood-brain barrier. Structurally, ketotifen shares similarities with certain first-generation antihistamines, including cyproheptadine and azatadine.[4] This structural relationship provides context for some of its pharmacological properties, notably the potential for central nervous system effects such as sedation, a characteristic often associated with first-generation antihistamines, despite ketotifen possessing additional mast cell stabilizing capabilities. This dual nature likely contributes to historical debate regarding its classification.[3]
• C. DrugBank Identification Ketotifen is cataloged in the DrugBank database under the identifier DB00920.3 It is classified as a Small Molecule drug type and falls under the Approved and Investigational groups, reflecting its status as a marketed drug in various regions and formulations, while potentially still being studied for other applications.1

II. Background and Development History

• A. Discovery and Initial Marketing Ketotifen originated in Switzerland, developed by Sandoz Pharmaceuticals (now part of Novartis) in 1970.4 Its initial therapeutic focus was on the treatment of anaphylaxis.4 Sandoz secured patents for the compound during the 1970s.22
• B. Evolution of Use and Formulations Following its introduction, oral ketotifen gained significant popularity for asthma management, particularly in Japan 22, where it became a market leader in the 1980s.23 This success spurred interest, leading to clinical trials in the United States during the 1980s, exploring its potential for asthma and other allergic conditions.22 However, despite undergoing review by the U.S. Food and Drug Administration (FDA) for asthma, approval for this indication was not granted.22 Notably, the FDA advisory committee at the time did recommend further investigation into its use for urticaria.22 The regulatory trajectory in the U.S. shifted towards ophthalmic applications. In 1999, the FDA approved Zaditor™, a 0.025% ketotifen fumarate ophthalmic solution (equivalent to 0.25 mg/mL ketotifen base), for the temporary prevention of itching associated with allergic conjunctivitis.[5] This marked the drug's entry into the U.S. market. Subsequently, other ophthalmic formulations gained approval, often transitioning to over-the-counter (OTC) status. Alaway® (0.035% ketotifen fumarate) received OTC approval in 2006 [28], followed by a preservative-free version, Alaway® Preservative Free, in 2020.[30] Innovation in delivery systems continued with the FDA approval in 2022 of Acuvue® Theravision™ with Ketotifen, the first drug-eluting daily disposable contact lens designed for both vision correction and prevention of ocular itch due to allergic conjunctivitis.[32] In contrast to the U.S. focus on ophthalmic use, oral ketotifen found a niche in Canada. Prescription-only syrup and tablet formulations became available as add-on therapy for the chronic treatment of mild atopic asthma in children.[4] The brand Zaditen® (Teva Canada Limited) was originally marketed in 1990 but its status is now listed as "Cancelled Post Market" in the Drug Product Database.[33] Other ophthalmic formulations remain approved or have dormant status in Canada.[35] Across Mexico and Europe, oral ketotifen has seen broader application and regulatory acceptance for various allergic symptoms and disorders, including asthma, urticaria, mastocytosis, and food allergy.[3] Periodic Safety Update Reports (PSURs) are managed by the European Medicines Agency (EMA) for both oral and ophthalmic formulations, indicating ongoing marketing and pharmacovigilance.[39] National authorizations for various ketotifen products exist across numerous EU member states.[18] Despite the lack of FDA approval for oral administration, ketotifen tablets and capsules are obtainable in the U.S. through compounding pharmacies upon prescription.[22] This practice suggests a perceived clinical need for its systemic effects, particularly its mast cell stabilizing properties, for conditions like severe urticaria or mast cell activation syndrome (MCAS), even in the absence of formal regulatory endorsement for these uses in the U.S. This complex regulatory history underscores a significant divergence in how ketotifen's risk-benefit profile, particularly for oral use in asthma, has been interpreted across different regions. The lack of FDA approval for oral asthma [22], despite its use for this indication elsewhere [4], suggests that factors such as the specific clinical trial data presented, the comparative efficacy against other available therapies in the U.S. market at the time of review, or differing regulatory standards may have influenced these decisions. Furthermore, the drug's evolution from an initial focus on severe allergic reactions and asthma towards widespread ophthalmic use and continued, albeit often off-label or compounded, oral use for mast cell-related disorders [4] highlights its perceived therapeutic versatility. The persistence of its use, particularly the mast cell stabilizing aspect, indicates that clinicians value its unique properties for conditions not fully addressed by standard antihistamines alone. The development of novel delivery systems like drug-eluting contact lenses [32] further demonstrates ongoing innovation based on its established ophthalmic efficacy.

III. Mechanism of Action and Pharmacology

• A. Dual Action: H1 Antagonism and Mast Cell Stabilization Ketotifen's pharmacological profile is characterized by two primary mechanisms of action that contribute to its anti-allergic effects. Firstly, it functions as a potent and relatively selective histamine H1 receptor antagonist.3 It binds to H1 receptors located on various target cells, including vascular endothelium, smooth muscle, and nerve endings, but does not activate them (non-competitive antagonism is also noted 5). This blockade prevents endogenous histamine from binding and eliciting its characteristic effects, thereby reducing symptoms such as itching, sneezing, vasodilation (leading to redness and swelling), and bronchoconstriction.3 Secondly, and distinctly, ketotifen acts as a mast cell stabilizer.[3] This property involves preventing the degranulation of mast cells upon encountering an allergen or other stimuli. By stabilizing these key immune cells, ketotifen inhibits the release of pre-formed mediators (like histamine) and newly synthesized inflammatory mediators. This action is particularly relevant for its prophylactic use in conditions like asthma and its application in mast cell-driven disorders such as mastocytosis and MCAS.[3] The combination of immediate symptom relief via H1 blockade and long-term prevention of mediator release via mast cell stabilization forms the basis of its therapeutic utility.
• B. Inhibition of Mediator Release Beyond histamine, ketotifen's mast cell stabilizing effect prevents the release of a broader array of inflammatory mediators. This includes leukotrienes C4 and D4 (LTC4, LTD4), which are potent bronchoconstrictors and components of what was formerly known as Slow Reacting Substance of Anaphylaxis (SRS-A), as well as prostaglandins and platelet-activating factor (PAF).3 Inhibition of mediator release has been demonstrated in vitro and is considered a key component of its anti-allergic and anti-inflammatory activity, contributing to its effectiveness beyond simple H1 antagonism.1 Some evidence suggests it may also inhibit mediator release from basophils and neutrophils.22
• C. Effects on Eosinophils Ketotifen has demonstrated effects on eosinophils, another important cell type in allergic inflammation, particularly in asthma. Studies indicate that it can decrease the chemotaxis (directed migration) and activation of eosinophils.5 Furthermore, it appears to suppress the "priming" of eosinophils by cytokines, a process that enhances their responsiveness, and thereby inhibits the influx of eosinophils into inflammatory sites, such as the airways in asthma.1 This anti-eosinophil activity likely contributes to its prophylactic effect in asthma.
• D. Other Pharmacological Activities Several additional mechanisms have been proposed or identified for ketotifen:
• Calcium Antagonism: Ketotifen exhibits calcium antagonist properties.[22] It may block calcium channels that are essential for the influx of calcium ions into mast cells, a critical step triggering degranulation.[3] This provides a potential molecular basis for its mast cell stabilizing effect.
• PAF Inhibition: It inhibits various biological processes mediated by platelet-activating factor (PAF), a potent lipid mediator involved in inflammation and allergy. These inhibited processes include PAF-induced airway hyperreactivity and the accumulation of eosinophils and platelets in the airways.[1]
• Leukotriene Antagonism: Ketotifen acts as a functional leukotriene antagonist, capable of preventing bronchoconstriction induced by leukotrienes.[3] This action complements its inhibition of leukotriene release from mast cells.
• Phosphodiesterase (PDE) Inhibition: Inhibition of cyclic adenosine monophosphate (cAMP) phosphodiesterase has been reported.[3] This could lead to increased intracellular cAMP levels, which generally has anti-inflammatory and smooth muscle relaxant effects.[22]
• β-Adrenoreceptor Modulation: There is some evidence suggesting ketotifen might reverse the downregulation of β2-adrenoreceptors caused by prolonged β2-agonist use and potentially alter receptor affinity.[22] This could theoretically restore sensitivity to bronchodilator therapy in asthma, although the clinical significance is uncertain.
• Enzyme Inhibition: Ketotifen has been identified as an inhibitor of the enzyme 6-phosphogluconate dehydrogenase, decarboxylating.[1] This enzyme is part of the pentose phosphate pathway. The relevance of this inhibition to ketotifen's primary therapeutic effects in allergy and asthma is not established based on the available information and may represent an off-target effect.
• Antiserotonergic/Anticholinergic: Weak activity at serotonin and cholinergic receptors has been noted, but these effects are generally considered clinically insignificant at standard therapeutic doses.[3]
• E. Onset and Duration of Action The onset and duration of ketotifen's effects vary by formulation and indication. Ophthalmic formulations provide rapid relief, with effects observed within minutes to 15 minutes after instillation.3 The duration of action for ophthalmic ketotifen is typically 8 to 12 hours.45 In contrast, the prophylactic effects of oral ketotifen, particularly for asthma, develop more slowly. While some clinical improvement may be seen earlier, it often takes 6 to 12 weeks of continuous treatment to achieve the full therapeutic benefit.3 This delay likely reflects the time required for the mast cell stabilizing and broader anti-inflammatory effects (e.g., reduction in eosinophil accumulation) to manifest fully, as opposed to the immediate effect of H1 receptor blockade.
• F. Molecular Targets Based on pharmacological data, the primary molecular target responsible for ketotifen's antihistaminic effect is the Histamine H1 receptor (HRH1), where it acts as an antagonist.1 A secondary molecular target identified is 6-phosphogluconate dehydrogenase, decarboxylating, which ketotifen inhibits.1 The mechanisms underlying its mast cell stabilization and other activities (e.g., calcium antagonism, PDE inhibition) involve broader cellular processes rather than single, specific receptor targets identified in the provided data.
• G. Significance of Multifaceted Mechanism The combination of H1 receptor antagonism, mast cell stabilization, inhibition of eosinophil activity, and potentially other actions like PAF and leukotriene antagonism provides a more comprehensive approach to managing allergic and inflammatory conditions compared to agents acting solely as antihistamines. This multifaceted profile explains its utility in complex conditions like asthma (prophylaxis) and MCAS, where multiple cell types and mediators contribute to pathophysiology.3 The distinction between the rapid symptomatic relief from H1 blockade (especially noticeable with ophthalmic use 5) and the delayed but sustained prophylactic benefits from mast cell stabilization and anti-inflammatory effects (requiring chronic oral administration 22) is a key aspect of its clinical pharmacology.

IV. Pharmacokinetics

• A. Absorption Ketotifen exhibits different absorption characteristics depending on the route of administration. Following oral intake, absorption from the gastrointestinal tract is generally rapid and nearly complete, with peak plasma concentrations (Cmax​) typically reached within 2 to 4 hours (Tmax​).3 Studies comparing formulations found that syrups might be absorbed slightly faster than capsules, based on Tmax​ values.62 The presence of food does not appear to significantly alter ketotifen's disposition, allowing for administration with or without meals.1 In contrast, systemic absorption following topical ophthalmic administration is minimal.3 Plasma concentrations after the application of ketotifen eye drops are frequently below the lower limit of quantification of analytical methods, indicating very low systemic exposure.46 Experimental studies in rabbits have also explored intranasal and rectal routes, showing rapid absorption via both, with intranasal administration yielding higher bioavailability than rectal administration in that model.20
• B. Distribution Once absorbed into the systemic circulation, ketotifen binds moderately to plasma proteins, with approximately 75% being protein-bound.3 The specific plasma proteins involved in binding have not been clearly identified in the reviewed materials.1 Information regarding the volume of distribution in humans was not available in the provided sources. Animal studies in rats indicated that after oral or intravenous administration, ketotifen distributes to various tissues, with the highest concentrations found in the liver, kidney, and lungs, and tissue levels declining in parallel with blood concentrations.57 Its lipophilic nature allows it to cross the blood-brain barrier, which is relevant to its potential central nervous system side effects, such as sedation.3
• C. Metabolism Ketotifen undergoes extensive metabolism in humans, primarily occurring in the liver.3 A significant first-pass effect following oral administration substantially reduces the amount of unchanged drug reaching systemic circulation.3 Several metabolic pathways have been identified. The major pathway is N-glucuronidation, accounting for the formation of ketotifen-N-glucuronide, which constitutes approximately 50% of the drug-related material excreted in urine.1 Other pathways include N-demethylation to form nor-ketotifen, and oxidation to form 10-hydroxyketotifen.1 Ketoreduction has also been suggested as a potential pathway, likely occurring in the cytosol.66 Nor-ketotifen, the N-demethylated metabolite, retains pharmacological activity comparable to the parent drug.3 However, it represents a smaller fraction of the metabolites found (around 10% of urinary excretion, though one source cites 2% 1), and its overall contribution to the clinical effect is considered uncertain due to its relatively low plasma concentrations.1 The 10-hydroxy metabolite is minor (<1-2% of urinary excretion) and inactive.3 The enzymes responsible for the major N-glucuronidation pathway have been identified as specific UDP-glucuronosyltransferases (UGTs), namely UGT1A3, UGT1A4, and UGT2B10.1 UGT2B10, in particular, has been highlighted for its role in the N-glucuronidation of tertiary amines.68 In vitro studies using human liver microsomes have confirmed their capability to perform N-glucuronidation.66 While specific cytochrome P450 (CYP) enzymes responsible for N-demethylation or hydroxylation are not explicitly identified for ketotifen in the provided snippets, CYP enzymes, particularly CYP3A4, are generally involved in the metabolism of similar antihistamines.3 The identification of specific UGT enzymes involved in ketotifen's primary metabolic pathway is significant. It provides a basis for predicting potential drug-drug interactions with substances that inhibit or induce UGT1A3, UGT1A4, or UGT2B10. Such interactions could alter ketotifen clearance, potentially affecting efficacy or increasing the risk of side effects. Furthermore, genetic variations (polymorphisms) in these UGT enzymes, although not detailed in the snippets, could contribute to inter-individual differences in response to ketotifen.64
• D. Excretion Elimination of ketotifen occurs predominantly via the kidneys, with over 60% of an administered dose being excreted in the urine, primarily in the form of metabolites.1 Unchanged ketotifen accounts for less than 1% of the urinary excretion. The major metabolites found in urine are the N-glucuronide (approximately 50%) and nor-ketotifen (approximately 10%).1 Fecal excretion also contributes to elimination.3
• E. Bioavailability The systemic bioavailability of oral ketotifen is estimated to be around 50% to 60%.3 This relatively low value, despite near-complete absorption, is attributed to the extensive first-pass metabolism in the liver. In contrast, systemic bioavailability following ophthalmic administration is negligible due to poor absorption across ocular tissues into the bloodstream.3 Experimental studies in rabbits showed intranasal bioavailability of ~66% and rectal bioavailability of ~34%.20 The pronounced first-pass effect necessitates oral doses sufficient to ensure adequate systemic exposure after hepatic clearance.
• F. Half-life Ketotifen exhibits biphasic elimination kinetics.1 The initial distribution phase has a half-life (t1/2α​) of approximately 3 to 5 hours.1 The terminal elimination phase half-life (t1/2β​) is reported with some variation across sources, typically cited as around 12 hours 3 or 22 hours.1 One study reported a mean of 12 hours with a range of 7 to 27 hours among subjects.62
• G. Pharmacokinetic Parameter Comparison (Oral vs. Ophthalmic) The pharmacokinetic profiles differ markedly between oral and ophthalmic administration routes, as summarized below:

*Table Value Rationale:* This table provides a concise comparison highlighting the critical pharmacokinetic differences between the two main routes of administration. Ketotifen's clinical use and safety profile differ significantly based on route. Oral use involves substantial systemic exposure and metabolism, leading to potential systemic side effects. Ophthalmic use targets local effects with minimal systemic absorption, reducing systemic risks. This table directly contrasts key parameters like bioavailability and metabolism, clarifying why the routes serve different indications and have distinct safety considerations.

• H. Implications of Pharmacokinetics The pharmacokinetic profile explains the different applications and dosing regimens. High first-pass metabolism necessitates higher oral doses for systemic effects compared to the microgram doses used ophthalmically for local action. The relatively long elimination half-life supports twice-daily dosing for both oral and ophthalmic routes. The existence of an active metabolite, nor-ketotifen, while apparently minor in concentration, adds a layer of complexity, as factors influencing its formation or clearance could theoretically modulate the drug's overall effect, though its clinical significance remains undefined.[1]

V. Clinical Applications and Efficacy

• A. Approved Indications
• Allergic Conjunctivitis (Ophthalmic Formulations): Ketotifen ophthalmic solutions (0.025% or 0.035%) and drug-eluting contact lenses are approved for the temporary prevention and relief of ocular itching associated with allergic conjunctivitis.3 This common condition is triggered by allergens such as pollen, ragweed, grass, or animal dander.30 Clinical studies, including conjunctival allergen challenge (CAC) models and environmental trials, have consistently demonstrated the efficacy of ketotifen eye drops compared to placebo.5 It significantly reduces ocular itching and associated signs like conjunctival hyperemia (redness). A key advantage is its rapid onset of action, providing relief within minutes to 15 minutes of application, and a sustained duration of effect lasting at least 8 to 12 hours, accommodating twice-daily dosing.3 Comparative efficacy data suggests ketotifen holds a favorable position. One environmental study found ketotifen 0.025% superior to levocabastine 0.05% ophthalmic suspension in relieving the signs and symptoms of seasonal allergic conjunctivitis (SAC).44 A meta-analysis further supports its efficacy over placebo for improving itching, tearing, and overall signs and symptoms.56 While clinical trials comparing ketotifen to other active agents like olopatadine, bilastine, and naphazoline have been conducted 74, detailed comparative results were not available in the provided snippets.
• Mild Atopic Asthma (Oral Formulation - Primarily Pediatric, Outside US): In regions like Canada and Europe, oral ketotifen (tablets or syrup) is indicated as an add-on therapy for the chronic treatment and prophylaxis of mild atopic asthma, primarily in children.4 It functions as a non-bronchodilator antiasthmatic agent and is not intended for the relief of acute asthma attacks or bronchospasm; patients require a separate rapid-onset rescue inhaler.24 Clinical evidence indicates that long-term administration (requiring 6-12 weeks for full effect) can reduce the frequency, severity, and duration of asthma symptoms and exacerbations.1 This may allow for a reduction in the need for concomitant asthma medications, such as rescue bronchodilators (e.g., salbutamol) or oral steroids.1 A systematic review focusing on pediatric use concluded that ketotifen provided good control of mild asthma symptoms in studies lasting 4 to 32 weeks.53 Comparative data against other asthma prophylactics is limited and somewhat mixed. A 12-week crossover study in skin test positive asthmatics found ketotifen 1 mg twice daily to be equivalent to sodium cromoglycate (SCG) 20 mg four times daily.79 However, another pediatric study comparing ketotifen syrup to SCG 5 mg aerosol found SCG to be superior in improving lung function and controlling symptoms.80 An early, short-term trial showed only a non-significant trend favoring ketotifen over placebo.81 This mixed evidence, particularly compared to inhaled standards like cromolyn, may have contributed to its lack of approval for asthma in the U.S..22
• B. Off-Label and Investigational Uses Ketotifen's unique pharmacological profile, particularly its mast cell stabilizing properties, has led to its use in various conditions beyond its formally approved indications, especially for the oral formulation in regions like the U.S. where it is obtained through compounding pharmacies.22
• Urticaria: It has been employed for diverse forms of urticaria, including chronic idiopathic urticaria (CIU), cold-induced, cholinergic, exercise-induced, pressure-induced, heat-induced urticaria, and dermatographism (urticaria factitia).[3] Several studies, many conducted in the 1980s, have evaluated its use, suggesting efficacy, particularly in cold and food-related urticaria, though some results were inconclusive.[22] Modern comparative data against current standard-of-care antihistamines (often used at higher doses for urticaria) is lacking in the provided snippets.[82]
• Mastocytosis and Mast Cell Activation Syndrome (MCAS): Oral ketotifen is frequently used off-label as a mast cell stabilizer in patients with mastocytosis and MCAS.[3] Its purported benefit lies in reducing mediator release, thereby alleviating systemic symptoms like flushing, gastrointestinal distress (abdominal pain, diarrhea, nausea), respiratory issues (wheezing), headache, and cognitive difficulties ("brain fog").[3]
• Food Allergy: Ketotifen has been studied and used in the context of food hypersensitivity.[3] Studies have shown a protective effect in oral food challenges, reducing the severity or preventing reactions.[55] One pediatric study suggested it was more effective than DSCG in preventing symptoms upon food challenge.[93] It has also been investigated as a premedication to attenuate allergic reactions during oral immunotherapy (OIT) for peanut allergy, potentially mitigating the common gastrointestinal side effects.[22]
• Other Allergic Conditions: Its use extends to allergic rhinitis [3] and atopic dermatitis (eczema) [3], leveraging its antihistaminic and anti-inflammatory properties.
• Investigational Areas: Clinical trial registries mention evaluations of oral ketotifen for conditions such as fibromyalgia [22] and post-traumatic joint contractures (based on the hypothesis that mast cells contribute to fibrosis).[22] Its potential role in pain management, particularly inflammatory pain potentially mediated by mast cells, has also been explored preclinically and in case reports.[85] A Phase II trial investigating ketotifen to enhance standard chemotherapy in sarcoma patients is also noted.[96]
• C. Summary of Clinical Trial Evidence The level of evidence supporting ketotifen's use varies by indication. For allergic conjunctivitis, multiple randomized controlled trials (RCTs), including CAC studies and environmental trials, robustly demonstrate superiority over placebo.5 Comparative trials against active agents like levocabastine, bilastine, naphazoline, and olopatadine have been conducted 44, with at least one study showing superiority over levocabastine.44 Meta-analyses confirm its efficacy.56 For asthma, pediatric trials indicate benefits over placebo in reducing symptoms and the need for rescue medications.53 However, comparisons with the older inhaled standard, sodium cromoglycate, have yielded mixed results.79 For urticaria, food allergy, and MCAS, the evidence base presented relies more heavily on older studies, open-label trials, case series, or extrapolation from its known mechanisms.22 While suggestive of benefit, particularly due to its mast cell stabilizing action, there is a relative lack of large, modern, high-quality RCTs confirming efficacy for these specific off-label uses according to current standards. This gap between perceived clinical utility and robust evidence highlights areas for potential future research.
• D. Summary of Efficacy Findings for Key Indications

*Table Value Rationale:* This table synthesizes core efficacy findings from the provided snippets across different indications and formulations. It allows for a quick comparison of evidence levels and effect direction for major uses (allergic conjunctivitis, asthma) and key off-label applications (food allergy, urticaria). Highlighting efficacy against placebo and active comparators provides a valuable summary for evaluating treatment options based on the source material.

VI. Dosage and Administration

• A. Ophthalmic Formulations
• Eye Drops (Ketotifen Fumarate 0.025% or 0.035%): The standard dosage for adults and children aged 3 years and older is one drop instilled into the affected eye(s) twice daily, typically every 8 to 12 hours.[5] It is explicitly advised not to exceed two doses per day.[72] These formulations are available both with preservatives (like benzalkonium chloride in multi-dose bottles) and as preservative-free single-use units.[30]
• Drug-Eluting Contact Lenses (Acuvue® Theravision™ with Ketotifen): These are daily disposable lenses, each containing 19 mcg of ketotifen. They are indicated for simultaneous vision correction (for patients with minimal astigmatism, ≤1.00 D) and prevention of ocular itch associated with allergic conjunctivitis. The anti-allergy effect lasts up to 12 hours, though the lens can be worn longer for vision correction purposes.[32] Use has not been studied in children under 11 years old.[3]
• Administration Advice: Proper instillation technique is important to maximize efficacy and minimize contamination. Patients should wash hands before use, tilt their head back, create a pocket by pulling down the lower eyelid, and instill one drop without touching the dropper tip to the eye or surrounding surfaces.[5] After instillation, closing the eye gently for 1-2 minutes and applying pressure to the tear duct can minimize systemic absorption.[7] If using other eye drops, a 5-minute interval should be observed between medications.[99] Contact lenses, particularly soft lenses which can absorb benzalkonium chloride from preserved solutions, should be removed before instilling ketotifen drops and reinserted after a waiting period of at least 10-15 minutes.[5] Contact lenses should not be worn if the eye is red.[5] The solution should be discarded if it appears cloudy or changes color.[72]
• B. Oral Formulations (Tablets, Syrup)
• Asthma/Allergic Disease (Adults and Children ≥ 3 years): The generally recommended dosage is 1 mg of ketotifen (equivalent to one 1 mg tablet or 5 mL of a 1 mg/5 mL syrup) administered twice daily, once in the morning and once in the evening.[22]
• Asthma/Allergic Disease (Infants/Children 6 months to 3 years): Dosing in this age group is typically based on body weight. A common recommendation is 0.05 mg per kilogram of body weight, given twice daily (morning and evening). For example, using a 1 mg/5 mL syrup, this corresponds to 0.25 mL of syrup per kilogram of body weight per dose.[24]
• Dose Titration: To mitigate the common initial side effect of sedation, a gradual dose increase over the first week of treatment is often advised. This might involve starting with half the target daily dose (divided into two administrations or given as a single evening dose) and increasing to the full therapeutic dose within approximately 5 days.[34]
• Administration: Oral ketotifen can be taken with or without food.[1]
• Compounded Capsules: In the United States, where oral ketotifen is not commercially approved by the FDA, it is frequently prepared by compounding pharmacies. Common strengths for compounded capsules are 0.5 mg and 1 mg, although other strengths like 0.25 mg, 2 mg, and 3 mg may also be prepared upon prescription.[43]

The significant difference in dosage magnitude between oral (milligrams) and ophthalmic (micrograms per drop) routes reflects their distinct targets – systemic versus local – and the major differences in absorption and bioavailability.[1] The need for weight-based dosing in young children [24] follows standard pediatric practice for systemic medications. Furthermore, the explicit recommendation for slow oral dose titration [34] is a practical measure directly linked to improving tolerance by minimizing the initial sedative effects.[22]

VII. Safety Profile

• A. Common Adverse Effects The side effect profile of ketotifen varies depending on the route of administration.
• Oral Administration: The most frequently reported side effect is sedation or drowsiness, occurring in approximately 10-20% of patients, particularly at the start of therapy or at higher doses; this effect often diminishes with continued use over 1-2 weeks.[3] Weight gain is also commonly reported, often linked to increased appetite.[3] Other relatively common effects include dry mouth and dizziness.[22] Paradoxical central nervous system (CNS) stimulation, manifesting as excitation, irritability, nervousness, or insomnia, can occur occasionally, particularly in children.[22] Less common effects include headache, nausea, diarrhea, muscle/joint aches, and flu-like symptoms.[22]
• Ophthalmic Administration: Local ocular effects are the most common. Conjunctival injection (eye redness) is reported frequently (incidence varies across studies, e.g., 7-25%).[5] Headaches (1.5-25%) and rhinitis (runny nose, 10-25%) are also relatively common non-ocular effects.[5] Local irritation upon instillation, such as burning or stinging, is frequent.[5] Other less common ocular effects (<5% or 0.1-10%) include dry eyes, eye pain, eye discharge, eyelid disorders, increased itching, photophobia (light sensitivity), blurred vision, tearing issues, mydriasis (pupil dilation), punctate keratitis, or corneal erosion.[5] Systemic effects are generally mild due to low absorption.[5]
• B. Serious Adverse Effects and Warnings While generally considered safe, particularly the ophthalmic formulation, certain serious adverse effects and warnings are associated with ketotifen, primarily with oral use.
• Thrombocytopenia: A rare but potentially serious adverse effect is a reversible decrease in platelet count (thrombocytopenia), which has been observed in patients taking oral ketotifen concurrently with oral antidiabetic agents.[1] This interaction warrants specific caution and monitoring (see Drug Interactions).
• Seizures/Epilepsy: Ketotifen may lower the seizure threshold. Convulsions have been reported very rarely during therapy. Therefore, it should be used with caution in individuals with a history of epilepsy or seizures. If a seizure occurs during treatment, ketotifen should be discontinued.[3]
• Hypersensitivity Reactions: As with most drugs, allergic reactions to ketotifen can occur, ranging from skin reactions (rash, hives, eczema exacerbation, contact dermatitis) to more severe systemic reactions like angioedema or, potentially, anaphylaxis.[5]
• Hepatotoxicity: Rare instances of elevated liver enzymes and hepatitis have been reported in association with oral ketotifen use.[34]
• Severe Skin Reactions: Extremely rare cases of severe skin reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported with oral ketotifen (approx. 1 case per 2 million patients).[34]
• CNS Depression: Due to its sedative potential, patients taking oral ketotifen should be warned about drowsiness and dizziness and advised to exercise caution when performing tasks requiring alertness, such as driving or operating machinery, especially during the initial phase of treatment.[24]
• Use in Asthma: Oral ketotifen is intended for prophylaxis and is not effective for treating acute asthma attacks. Patients must have access to appropriate rescue medication.[24]
• Ophthalmic Use Specifics: Ketotifen eye drops are strictly for topical ophthalmic use and must not be injected or ingested.[5] They should not be used to treat irritation caused by contact lenses.[5] Patients should avoid wearing contact lenses if their eyes are red.[5] The preservative benzalkonium chloride, present in many multi-dose formulations, can be absorbed by soft contact lenses, necessitating lens removal before instillation and a waiting period before reinsertion.[5]
• C. Contraindications Ketotifen is contraindicated in individuals with:
• Known hypersensitivity to ketotifen or any excipients in the specific formulation.[3]
• Acute porphyrias.[3] Some sources or specific product labels may also list concomitant use with oral antidiabetic agents (particularly biguanides) as a contraindication due to the risk of thrombocytopenia.[105] Epilepsy is often listed as a condition requiring caution rather than an absolute contraindication.[3]
• D. Precautions
• Withdrawal: If discontinuing oral ketotifen therapy, gradual tapering over a period of 2 to 4 weeks is recommended to avoid potential rebound effects.[57]
• Concomitant Asthma Therapy: When initiating oral ketotifen for asthma, existing asthma medications, especially systemic corticosteroids, should not be reduced abruptly. Gradual tapering under medical supervision is necessary, recognizing that recovery of adrenal function can take time.[24]
• Diabetes Mellitus: Patients with diabetes using the oral syrup formulation should be aware of its carbohydrate content and monitor blood glucose levels accordingly.[24] Benzoate-free tablet formulations are available.[57]
• Anticholinergic Effects: Although weak, ketotifen's potential anticholinergic activity warrants caution in patients with conditions like pyloroduodenal obstruction, susceptibility to angle-closure glaucoma, or urinary retention.[3]
• E. Drug Interactions Clinically significant drug interactions primarily involve oral ketotifen:
• Oral Antidiabetic Agents: As previously noted, there is a rare risk of reversible thrombocytopenia when oral ketotifen is used concurrently with oral antidiabetic drugs.[1] Some guidelines recommend avoiding this combination, while others advise monitoring platelet counts.[57] The exact mechanism for this interaction is not well-defined in the provided sources, though potential effects of antidiabetic agents on platelets exist generally.[106]
• CNS Depressants: Ketotifen can potentiate the sedative effects of other CNS depressants, including alcohol, sedatives, hypnotics, and other antihistamines.[22] Patients should be advised to avoid alcohol and use caution with concomitant CNS depressant medications.
• Anticoagulants: Potential potentiation of anticoagulant effects has been mentioned, requiring caution.[105]
• Other Specific Drugs: Interactions are listed with agents like amifampridine, bupropion, donepezil, and pitolisant (concurrent use usually not recommended or requires caution).[24] Ketotifen may decrease the efficacy of betahistine [1] and increase the efficacy of certain sympathomimetics (e.g., epinephrine).[1] Additive anticholinergic effects may occur with other anticholinergic drugs (e.g., hyoscyamine).[1] Stimulants like amphetamines may counteract ketotifen's sedative effects.[1]
• F. Clinically Significant Drug Interactions Summary

*Table Value Rationale:* This table consolidates key drug interactions, focusing on clinical consequences and management advice derived from the sources. It highlights the most significant interactions, particularly the unique thrombocytopenia warning with oral antidiabetics, aiding clinicians in safe prescribing.

• G. Use in Specific Populations
• Pediatrics: Ophthalmic solutions are generally approved for use in children aged 3 years and older; safety and efficacy below this age are not established.[5] Drug-eluting contact lenses have not been studied below age 11.[3] Oral ketotifen has been tested in children and is approved in some regions for pediatric asthma down to 6 months of age, with weight-based dosing for younger children.[24] CNS stimulation (excitation, irritability) may be more common in children taking oral ketotifen.[24]
• Geriatrics: Specific studies comparing the effects or safety of ketotifen in older adults versus younger adults are lacking.[24] Standard precautions for medications with sedative potential should apply.
• Pregnancy: There are no adequate studies in pregnant women to establish safety. Animal reproduction studies using high oral doses did not show relevant embryofetal toxicity.[26] Oral ketotifen should only be used during pregnancy if the potential benefit justifies the potential risk.[34]
• Lactation: Ketotifen is excreted into the breast milk of rats following oral administration.[5] It is unknown if topical ocular use results in significant amounts in human breast milk, but caution is advised.[5] Systemic absorption from eye drops is likely low, potentially posing minimal risk to the infant.[7] However, some sources advise against breastfeeding while taking oral ketotifen.[102] The potential benefits versus risks should be weighed.[24]
• H. Safety Profile Implications The safety profile clearly differs between routes of administration. Oral use carries systemic risks, primarily sedation and weight gain, along with rarer but serious concerns like potential seizure threshold lowering and the specific interaction with oral antidiabetics causing thrombocytopenia.22 Ophthalmic use is associated mainly with local irritation, with minimal systemic risk due to low absorption.5 This difference strongly influences indication selection and patient counseling. The thrombocytopenia interaction, though rare and mechanistically unclear, is a recurring warning in official documentation and represents a specific vigilance point for patients on concomitant therapy.22 The potential to lower the seizure threshold also distinguishes ketotifen from many other antihistamines, requiring careful consideration in patients with epilepsy.24

VIII. Regulatory Status

• A. FDA (United States) The regulatory status of ketotifen in the United States is specific to its formulation.
• Ophthalmic Formulations: Ketotifen is approved by the FDA for ophthalmic use, indicated for the temporary relief or prevention of itching associated with allergic conjunctivitis. The initial approval was for Zaditor® (0.025% solution) in 1999 under NDA 21-066.[5] This was followed by the approval of Alaway® (0.035% solution) in 2006 under NDA 21-996, which was approved directly for OTC use.[28] Further developments include the approval of a preservative-free formulation, Alaway® Preservative Free (0.035%), in 2020, marking the first OTC preservative-free option for this indication.[30] Most recently, in 2022, the FDA approved Acuvue® Theravision™ with Ketotifen, the first drug-eluting daily disposable contact lens combining vision correction with allergy itch prevention.[32]
• Oral Formulations: Oral ketotifen is not approved by the FDA for any indication.[22] It underwent review for asthma in the 1980s, spurred by its use in Japan, but did not receive approval.[22] Despite this lack of formal approval, oral ketotifen can be obtained in the U.S. through compounding pharmacies when prescribed by a physician, often for off-label uses like MCAS or severe urticaria.[22]
• B. Health Canada In Canada, both oral and ophthalmic formulations have regulatory standing.
• Oral Formulations: Ketotifen (as tablets or syrup) is approved as a prescription drug (Schedule: Prescription Recommended).[33] Its primary indication is as an add-on therapy for the long-term management of mild atopic asthma in children.[4] The brand name Zaditen® (DIN 00600784), originally marketed by Teva Canada Limited from 1990, is listed in the Drug Product Database with a status of "Cancelled Post Market" as of 2021.[33]
• Ophthalmic Formulations: Ketotifen ophthalmic solutions are approved in Canada. Examples include JAMP-KETOTIFEN (DIN 02489651), which holds an "Approved" status [36], and a Sterimax Inc. product (DIN 02400871), which has been listed as "Dormant" since August 2021.[35] A "Dormant" status signifies that the product has not been sold on the Canadian market for 12 consecutive months but has not been formally discontinued by the manufacturer.[37]
• Summary Basis of Decision (SBD): While Health Canada publishes SBDs explaining the rationale for drug approvals, specific SBD documents for ketotifen products were not identified within the provided search results or links.[110]
• C. EMA (Europe) / Other Regions Ketotifen enjoys broader regulatory acceptance, particularly for oral use, in Europe and other parts of the world.
• Oral Formulations: Oral ketotifen is widely used and approved in Mexico and numerous European countries for a range of allergic conditions, including asthma, allergic rhinitis, urticaria, mastocytosis, and food allergies.[3] National authorizations exist across various EU member states.[18] The EMA oversees Periodic Safety Update Report (PSUR) procedures for oral formulations (e.g., PSUSA/00001813/201410), indicating ongoing regulatory oversight.[40] Approved pediatric use can extend down to 6 months of age in some EU countries.[38]
• Ophthalmic Formulations: Ophthalmic ketotifen solutions are also approved and marketed throughout Europe.[18] Both multi-dose preserved formulations and single-dose preservative-free options are available, including generic versions.[18] An EMA PSUR procedure specifically for ophthalmic formulations (PSUSA/00001812/202206) is also in place.[39]
• Other Regions: Ketotifen has a history of use in other regions. For instance, ophthalmic ketotifen (Zaditen® 0.025%) underwent reclassification from Prescription Medicine to Pharmacist Only Medicine in New Zealand.[63] It has been marketed ophthalmically in Japan since 1991, and the oral form was previously a significant asthma medication there.[23]
• D. Regulatory History Summary Ketotifen's journey began with its development by Sandoz in the 1970s. While the oral form gained acceptance for asthma treatment outside the U.S., it failed to secure FDA approval for this use. In the U.S., the focus shifted to ophthalmic applications, leading to initial Rx approval in 1999, followed by successful Rx-to-OTC switches and the introduction of advanced formulations like preservative-free drops and drug-eluting contact lenses. In contrast, oral ketotifen remains available by prescription in Canada (for pediatric asthma) and is more broadly approved and utilized in Europe and Mexico for asthma and various other allergic conditions. Its availability in the U.S. relies on compounding pharmacies for off-label indications.
• E. Implications of Regulatory Status The markedly fragmented global regulatory status of ketotifen, especially for its oral form, is a defining characteristic. The disparity between its non-approval for oral use by the FDA and its acceptance in Canada, Europe, and elsewhere reflects differing historical contexts, regulatory assessments of efficacy (particularly for asthma relative to other available treatments), and potentially varying market demands. This complex regulatory landscape directly impacts its availability and labeled indications worldwide. The successful evolution of the ophthalmic formulation in the U.S. market – from prescription to OTC, and incorporating innovations like preservative-free options and drug-eluting lenses 26 – indicates strong market acceptance for its approved indication and a focus on enhancing patient convenience and addressing specific needs within that niche. This contrasts sharply with the static regulatory situation for the oral form in the U.S.

IX. Conclusion

• A. Summary of Ketotifen's Profile Ketotifen is a pharmacologically unique agent characterized by its dual action as both a histamine H1 receptor antagonist and a mast cell stabilizer.3 This profile differentiates it from traditional antihistamines. It is available in oral (tablet, syrup) and ophthalmic (eye drops, drug-eluting contact lens) formulations, which possess distinct pharmacokinetic properties leading to different primary applications: systemic prophylaxis for oral forms versus local symptom relief for ophthalmic forms.3 Key approved indications include allergic conjunctivitis (ophthalmic, widely approved including US OTC) and mild atopic pediatric asthma (oral, approved outside the US, e.g., Canada, Europe).3 Off-label use, particularly of compounded oral forms in the US, is common for conditions like urticaria, mastocytosis/MCAS, and food allergies.22 The safety profile is generally manageable but notable side effects include sedation and weight gain with oral use, local irritation with ophthalmic use, and a rare but significant interaction between oral ketotifen and oral antidiabetic agents leading to thrombocytopenia.22
• B. Key Therapeutic Roles and Limitations For allergic conjunctivitis, ketotifen ophthalmic formulations represent a valuable therapeutic option, offering rapid onset, sustained duration of action, and efficacy demonstrated against placebo and some active comparators, attributable to its combined H1 antagonism and mast cell stabilizing effects.5 In asthma prophylaxis, oral ketotifen's role is established in certain regions, especially for mild atopic asthma in children.53 However, its efficacy may be less robust compared to modern inhaled therapies, and its full benefit requires several weeks of continuous administration.57 The drug's mast cell stabilizing properties drive its potential utility in mast cell-mediated disorders like MCAS, various urticarias, and food allergies.22 While clinical experience and older studies support this use, there is a need for more high-quality, contemporary clinical trial evidence to solidify its place in therapy for these conditions, particularly in regions like the U.S. where it lacks formal oral approval. While generally well-tolerated, the potential for sedation with oral use can impact daily activities, and the specific risk of thrombocytopenia when combined with oral antidiabetic agents necessitates careful consideration and patient monitoring.22
• C. Final Assessment Ketotifen remains a clinically relevant medication primarily due to its distinctive combination of antihistaminic and mast cell stabilizing activities. This dual mechanism provides a broader spectrum of action than typical antihistamines, making it suitable for both acute symptom relief (ophthalmic) and long-term prophylaxis (oral). However, its therapeutic landscape is complex, shaped by significant regional variations in regulatory approval, particularly for the oral formulation. Formulation-dependent pharmacokinetics dictate its use and safety considerations. While its efficacy in allergic conjunctivitis is well-established, further high-quality research is warranted to fully define its role and comparative effectiveness in asthma and various off-label applications like MCAS and urticaria according to current evidence standards.

Works cited

1. Ketotifen: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed April 30, 2025, https://go.drugbank.com/drugs/DB00920
2. Ketotifen | C19H19NOS - ChemSpider, accessed April 30, 2025, https://www.chemspider.com/Chemical-Structure.3695.html
3. Ketotifen - Wikipedia, accessed April 30, 2025, https://en.wikipedia.org/wiki/Ketotifen
4. Ketotifen | C19H19NOS | CID 3827 - PubChem, accessed April 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ketotifen
5. s3-us-west-2.amazonaws.com, accessed April 30, 2025, https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00920.pdf?1265922796
6. CHEBI:92511 - ketotifen - EMBL-EBI, accessed April 30, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:92511
7. Ketotifen Fumarate | C23H23NO5S | CID 5282408 - PubChem, accessed April 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ketotifen-Fumarate
8. Ketotifen fumarate, 99%, Thermo Scientific Chemicals, accessed April 30, 2025, https://www.thermofisher.com/order/catalog/product/tw/en/J63708.03
9. Ketotifen - brand name list from Drugs.com, accessed April 30, 2025, https://www.drugs.com/ingredient/ketotifen.html
10. Cas no 34580-13-7 (Ketotifen), accessed April 30, 2025, https://m.chem960.com/lang_en/cas_34580137/
11. Ketotifen 34580-14-8 - Sigma-Aldrich, accessed April 30, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/k2628
12. Ketotifen [INN:BAN] - PubChem, accessed April 30, 2025, https://pubchem.ncbi.nlm.nih.gov/substance/134999546
13. Chemical Substance Search - OECD eChemPortal, accessed April 30, 2025, https://www.echemportal.org/echemportal/substance-search?query_term=34580-13-7
14. ketotifen | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed April 30, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7206
15. Drug Information | Therapeutic Target Database, accessed April 30, 2025, https://db.idrblab.net/ttd/data/drug/details/D0YG7M
16. Ketotifen fumarate | CAS 34580-14-8 | SCBT - Santa Cruz Biotechnology, accessed April 30, 2025, https://www.scbt.com/p/ketotifen-fumarate-34580-14-8
17. Ketotifen fumarate | DrugBank Online, accessed April 30, 2025, https://go.drugbank.com/salts/DBSALT001856
18. Public Assessment Report Scientific discussion Ketotifen Stulln 0.25 mg/ml eye drops, solution in single-dose container (ketotif - Geneesmiddeleninformatiebank, accessed April 30, 2025, https://www.geneesmiddeleninformatiebank.nl/pars/h123621.pdf
19. Public Assessment Report Ketotifen Bipharma 0.25 mg/ml single dose, eye-drops, solution, accessed April 30, 2025, https://ogyei.gov.hu/kiseroirat/ph/ph_0000120238.pdf
20. Yagi N, Taniuchi Y, Hamada K, Sudo J, Sekikawa H. Pharmacokinetics of ketotifen fumarate after intravenous, intranasal, oral and rectal administration in rabbits. Biol Pharm Bull 25: 1614-1618 - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/10975055_Yagi_N_Taniuchi_Y_Hamada_K_Sudo_J_Sekikawa_H_Pharmacokinetics_of_ketotifen_fumarate_after_intravenous_intranasal_oral_and_rectal_administration_in_rabbits_Biol_Pharm_Bull_25_1614-1618?_share=1
21. Eye pruritus | DrugBank Online, accessed April 30, 2025, https://go.drugbank.com/indications/DBCOND0009874
22. Ketotifen in the management of chronic urticaria: resurrection of an old drug - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4309375/
23. SANDOZ' ORAL ANTIALLERGIC ZADITEN (KETOTIFEN) IS A JAPANESE MARKET LEADER IN ASTHMA WITH ANNUAL SALES AT $60 MIL.: U.S., APPROVAL COULD BE NEAR, SRI SAYS, accessed April 30, 2025, https://insights.citeline.com/PS011086/SANDOZ-ORAL-ANTIALLERGIC-ZADITEN-KETOTIFEN-IS-A-JAPANESE-MARKET-LEADER-IN-ASTHMA-WITH-ANNUAL-SALES-AT-60-MIL-US-APPROVAL-COULD-BE-NEAR-SRI-SAYS/
24. Ketotifen (Oral) Advanced Patient Information - Drugs.com, accessed April 30, 2025, https://www.drugs.com/cons/ketotifen-oral.html
25. Case Number: 202203-147188 | Department of Financial Services, accessed April 30, 2025, https://www.dfs.ny.gov/public-appeals/case-number-202203-147188
26. ZADITOR™ ketotifen fumarate ophthalmic solution, 0.025% DESCRIPTION ZADITOR™ is a sterile ophthalmic solution containing ket - accessdata.fda.gov, accessed April 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21066lbl.pdf
27. All About Ketotifen - Oregon Association of Naturopathic Physicians, accessed April 30, 2025, https://www.oanp.org/news/683352/Ketotifen.htm
28. Alaway (ketotifen ophthalmic) FDA Approval History - Drugs.com, accessed April 30, 2025, https://www.drugs.com/history/alaway.html
29. Drug Approval Package: Alaway (ketotifen fumarate ophthalmic solution) NDA #021996, accessed April 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021996_alaway_toc.cfm
30. FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035% - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/news-releases/fda-approves-bausch--lomb-alaway-preservative-free-ketotifen-fumarate-ophthalmic-solution-0-035-301138158.html
31. FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035% | Eton Pharmaceuticals, Inc., accessed April 30, 2025, https://ir.etonpharma.com/news-releases/news-release-details/fda-approves-bausch-lomb-alawayr-preservative-free-ketotifen/
32. FDA approves first drug-eluting contact lens - Healio, accessed April 30, 2025, https://www.healio.com/news/optometry/20220302/fda-approves-first-drugeluting-contact-lens
33. From Health Canada - Product information, accessed April 30, 2025, https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10860
34. pdf.hres.ca, accessed April 30, 2025, https://pdf.hres.ca/dpd_pm/00067932.PDF
35. Details for: KETOTIFEN OPHTHALMIC SOLUTION - Drug and Health Products Portal, accessed April 30, 2025, https://dhpp.hpfb-dgpsa.ca/dhpp/resource/88567
36. Details for: JAMP-KETOTIFEN - Drug and Health Products Portal, accessed April 30, 2025, https://dhpp.hpfb-dgpsa.ca/dhpp/resource/97973
37. Dormant drug status can trigger generic access to an alternate Canadian Reference Product, accessed April 30, 2025, https://www.pharmainbrief.com/2024/02/dormant-drug-status-can-trigger-generic-access-to-an-alternate-canadian-reference-product/
38. Off-label prescribing for allergic diseases in pre-school children | Allergologia et Immunopathologia - Elsevier, accessed April 30, 2025, https://www.elsevier.es/en-revista-allergologia-et-immunopathologia-105-articulo-off-label-prescribing-for-allergic-diseases-S0301054613001110
39. PSUSA/00001812/202206 - periodic safety update report single assessment | European Medicines Agency (EMA), accessed April 30, 2025, https://www.ema.europa.eu/en/medicines/psusa/psusa-00001812-202206
40. ketotifen (oral formulations) - Infarmed, accessed April 30, 2025, https://www.infarmed.pt/documents/15786/17838/cetotifeno_formulacoes_orais.pdf/5773498a-fd17-401a-9af4-893a47eefeae?version=1.0
41. ketotifen (ophthalmic formulations): List of nationally authorised medicinal products - PSUSA/00001812/202206 - EMA, accessed April 30, 2025, https://www.ema.europa.eu/en/documents/psusa/ketotifen-ophthalmic-formulations-list-nationally-authorised-medicinal-products-psusa00001812202206_en.pdf
42. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands Ketotifen Eberth Unit Dose 0.25 mg/ml eye drops, - Geneesmiddeleninformatiebank, accessed April 30, 2025, https://www.geneesmiddeleninformatiebank.nl/pars/h110580.pdf
43. Ketotifen: Comprehensive Overview - CareFirst Specialty Pharmacy, accessed April 30, 2025, https://www.cfspharmacy.pharmacy/blog/post/ketotifen-comprehensive-overview
44. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1920791/
45. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/12742839/
46. Ketotifen Fumarate Ophthalmic Solution, accessed April 30, 2025, https://pdf.hres.ca/dpd_pm/00019014.PDF
47. Ketotifen Fumarate Ophthalmic Solution - Sterimaxinc, accessed April 30, 2025, https://sterimaxinc.com/wp-content/uploads/2016/03/SteriMax-English-PM-February-8-2016.pdf
48. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7007452/
49. The Mast Cell Stabilizer Ketotifen Fumarate Lessens Contracture Severity and Myofibroblast Hyperplasia - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3033391/
50. Mast Cell Stabilization Decreases Cardiomyocyte and LV Function in Dogs with Isolated Mitral Regurgitation - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3865763/
51. Twenty-first century mast cell stabilizers - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3764846/
52. Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4417653/
53. Ketotifen alone or as additional medication for long‐term control of asthma and wheeze in children - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8406918/
54. Ketotifen: current views on its mechanism of action and their therapeutic implications - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/6206536/
55. A study of the protective effect of ketotifen in food allergy - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/7457290/
56. Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9922628/
57. PRODUCT MONOGRAPH ZADITEN® (ketotifen fumarate) Tablets 1 mg Syrup 1 mg/5 mL Pediatric Asthma Prophylactic and Antiallergic Age, accessed April 30, 2025, https://pdf.hres.ca/dpd_pm/00017437.PDF
58. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/2226222/
59. Ketotifen Capsules - Harbor Compounding Pharmacy, accessed April 30, 2025, https://www.harborcompounding.com/ketotifen-capsules
60. Mechanism of ketotifen action in hypersensitivity reactions. Its effect on cellular enzymatic activities - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/1669589/
61. Ketotifen (oral route) - Mayo Clinic, accessed April 30, 2025, https://www.mayoclinic.org/drugs-supplements/ketotifen-oral-route/description/drg-20064435
62. Pharmacokinetics of ketotifen after oral administration to healthy male subjects - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/1600111/
63. agen32-ketotifen.pdf - Medsafe, accessed April 30, 2025, https://www.medsafe.govt.nz/profs/class/Agendas/agen32-ketotifen.pdf
64. Full article: The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure - Taylor & Francis Online, accessed April 30, 2025, https://www.tandfonline.com/doi/full/10.1080/03602532.2023.2297154
65. Ketotifen : Indications, Uses, Dosage, Drugs Interactions, Side effects - Medical Dialogues, accessed April 30, 2025, https://medicaldialogues.in/generics/ketotifen-2722983
66. Metabolism of ketotifen by human liver microsomes. In vitro characterization of a tertiary amine glucuronidation - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/6140144/
67. The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human Diseases, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8231948/
68. N-Glucuronidation of Drugs and Other Xenobiotics - Helda - Helsinki.fi, accessed April 30, 2025, https://helda.helsinki.fi/server/api/core/bitstreams/7111f642-7e76-479d-8eb5-933e2b1912b2/content
69. A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement | Drug Metabolism & Disposition - Resolve a DOI Name, accessed April 30, 2025, https://dx.doi.org/10.1124/dmd.114.062620
70. SYSTEM-DEPENDENT METABOLISM OF DRUGS BY CYTOCHROME P450: THE MECHANISTIC BASIS FOR WHY HUMAN LIVER MICROSOMES ARE SUPERIOR TO HU - KU ScholarWorks, accessed April 30, 2025, https://kuscholarworks.ku.edu/server/api/core/bitstreams/ca159b58-58ea-405b-8605-a09572568882/content
71. (PDF) The potential impact of CYP and UGT drug metabolizing enzymes on brain target site drug exposure - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/376748093_The_potential_impact_of_CYP_and_UGT_drug_metabolizing_enzymes_on_brain_target_site_drug_exposure
72. Ketotifen Ophthalmic Dosage Guide + Max Dose, Adjustments ..., accessed April 30, 2025, https://www.drugs.com/dosage/ketotifen-ophthalmic.html
73. Ketotifen: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed April 30, 2025, https://www.medcentral.com/drugs/monograph/17383-399018/ketotifen-ophthalmic-eye
74. Ketotifen Completed Phase 3 Trials for Allergic Conjunctivitis (AC) Treatment - DrugBank, accessed April 30, 2025, https://go.drugbank.com/drugs/DB00920/clinical_trials?conditions=DBCOND0076634&phase=3&purpose=treatment&status=completed
75. Ketotifen Completed Phase 3 Trials for Allergic Conjunctivitis (AC) | DrugBank Online, accessed April 30, 2025, https://go.drugbank.com/drugs/DB00920/clinical_trials?conditions=DBCOND0076634&phase=3&status=completed
76. Ketotifen Completed Phase 2 Trials for Allergic Conjunctivitis (AC) Treatment - DrugBank, accessed April 30, 2025, https://go.drugbank.com/drugs/DB00920/clinical_trials?conditions=DBCOND0076634&phase=2&purpose=treatment&status=completed
77. Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/36816214/
78. Ketotifen in the prophylaxis of extrinsic bronchial asthma. A multicenter controlled double-blind study with a modified-release formulation - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/2684551/
79. A comparison of the efficacy of ketotifen (HC 20-511) with sodium cromoglycate (SCG) in skin test positive asthma - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/6108129/
80. A double-blind, placebo-controlled comparison of sodium cromoglycate and ketotifen in the treatment of childhood asthma - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/7573849/
81. Ketotifen in childhood asthma: a double-blind placebo controlled trial - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/380838/
82. H1‐antihistamines for chronic spontaneous urticaria - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6481497/
83. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/32916325/
84. Second-generation antihistamines: a comparative review - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/9951950/
85. Mast cell stabilizer ketotifen fumarate reverses inflammatory but not neuropathic-induced mechanical pain in mice - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8177879/
86. Non-Clonal Mast Cell Activation: A Growing Body of Evidence - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6049091/
87. Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders? - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7003574/
88. Mast cell stabilization: novel medication for obesity and diabetes - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3318912/
89. Mast Cell-Mediated Mechanisms of Nociception - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4691098/
90. Distinct Small Intestine Mast Cell Histologic Changes in Patients with Hereditary Alpha-Tryptasemia and Mast Cell Activation Syndrome - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8192345/
91. Immunological dysfunction and mast cell activation syndrome in long COVID - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10166245/
92. Ketotifen treatment of adverse reactions to foods: clinical and immunological effects, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/2949941/
93. Comparison of ketotifen and DSCG in treatment of food allergy in children - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/3103406/
94. Effect of ketotifen premedication on adverse reactions during peanut oral immunotherapy - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4099498/
95. Ketotifen Completed Phase 3 Trials for Perennial Allergic Rhinitis (PAR) Treatment, accessed April 30, 2025, https://go.drugbank.com/drugs/DB00920/clinical_trials?conditions=DBCOND0058482&phase=3&purpose=treatment&status=completed
96. Search for eudract_number:2022-002311-39 - Clinical Trials register, accessed April 30, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-002311-39
97. EU Clinical Trials Register, accessed April 30, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002311-39/CY
98. Ketotifen (ophthalmic route) - Mayo Clinic, accessed April 30, 2025, https://www.mayoclinic.org/drugs-supplements/ketotifen-ophthalmic-route/description/drg-20064429
99. Ketotifen Ophthalmic: MedlinePlus Drug Information, accessed April 30, 2025, https://medlineplus.gov/druginfo/meds/a604033.html
100. Ketotifen Ophthalmic: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed April 30, 2025, https://www.rxlist.com/ketotifen_ophthalmic/generic-drug.htm
101. Ketotifen (Zaditor, Alaway, Children's Alaway): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed April 30, 2025, https://www.webmd.com/drugs/2/drug-17383/ketotifen-ophthalmic-eye/details
102. Ketotifen (Systemic: Pediatric Medication | Memorial Sloan Kettering Cancer Center, accessed April 30, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/ketotifen-systemic
103. Ketotifen Ophthalmic Side Effects: Common, Severe, Long Term - Drugs.com, accessed April 30, 2025, https://www.drugs.com/sfx/ketotifen-ophthalmic-side-effects.html
104. Side Effects - ketotifen fumarate - BuzzRx, accessed April 30, 2025, https://www.buzzrx.com/ketotifen%20fumarate/side-effects
105. Summary of Product Characteristics - HPRA, accessed April 30, 2025, https://assets.hpra.ie/products/Human/28769/Licence_PA2206-004-002_29012021115246.pdf
106. Effect of ketotifen in obese patients with type 2 diabetes mellitus - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/25704652/
107. Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.670155/full
108. center for drug evaluation and - accessdata.fda.gov, accessed April 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021996s000_PharmR.pdf
109. Health Canada Drug Product Database - Schedule - HL7 Terminology (THO) v6.3.0, accessed April 30, 2025, https://build.fhir.org/ig/HL7/UTG/branches/master/CodeSystem-ca-hc-dpd-schedule.html
110. Summary Basis of Decision for Uplizna - Drug and Health Products Portal, accessed April 30, 2025, https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1722001162962
111. Summary Basis of Decision Search Results - Drug and Health Product Register, accessed April 30, 2025, https://hpr-rps.hres.ca/reg-content/summary-basis-decision-result.php?lang=en&term=
112. Trends in licence approvals for ophthalmic medicines in the United Kingdom - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7608198/
113. Allergic Conjunctivitis Management: Update on Ophthalmic Solutions - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11233348/